Join us for an important webinar focused on understanding how well available information on the cost-effectiveness of health interventions aligns with diseases and conditions that contribute the greatest global burden. We will explore where the gaps are greatest, how this varies by location, disease, and type of intervention, and discuss policy options for improving the alignment. Our discussion is particularly relevant now that health systems around the world are struggling with how best to respond to the COVID-19 pandemic, and what lessons can be learned for future outbreak prevention and control.
Peter Neumann, ScD, Director, Center for the Evaluation of Value and Risk in Health
Peter Neumann is the Director of CEVR at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. He is the founder and director of the Cost-Effectiveness Analysis Registry, a comprehensive database of cost-effectiveness analyses in health care.
Dan Ollendorf, PhD, Director, Value Measurement & Global Health Initiatives, Center for the Evaluation of Value and Risk in Health
Dan Ollendorf is Director of Value Measurement and Global Health Initiatives at CEVR and Assistant Professor of Medicine at Tufts University School of Medicine. His research interests include expanding the use of health technology assessment (HTA) and economic evaluation in low- and middle-income countries, as well as refinement and use of value assessment tools in the US and other high-income settings.
Amanda Glassman, MSc, Executive Vice President of the Center for Global Development (CGD), CEO of CGD Europe, and Senior Fellow
Amanda Glassman is Executive Vice President and Senior Fellow at the Center for Global Development and also serves as chief executive officer of CGD Europe. Her research focuses on priority-setting, resource allocation, and value for money in global health, as well as data for development.